Delivery Order SPE2DB22D1202-SPE2DB25FVJZ2
- Not listed
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp on September 10, 2025, for the supply of Envarsus XR 1 mg tablets in quantities of 100 units, with a contract ceiling value of $1,718.48. This firm fixed-price delivery order, with an ultimate completion date of October 1, 2025, represents a non-set-aside competitive award to support federal medical procurement requirements. The award is issued under AmerisourceBergen's larger Indefinite Delivery...
- The Defense Logistics Agency awarded a delivery order valued at $3,423.90 to AmerisourceBergen Drug Corp for the supply of Envarsus XR 4 mg tablets (100-count bottles) on August 25, 2025, with completion scheduled for September 16, 2025. This firm fixed-price delivery order represents a non-set-aside competitive award to the pharmaceutical distributor's corporate office in Conshohocken, Pennsylvania. The contract is issued as a child order under AmerisourceBergen's larger Indefinite Delivery...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $5,370.76 to AmerisourceBergen Drug Corp for Envarsus XR 1 mg tablets (100 count) on July 31, 2025, with completion scheduled for August 21, 2025. This non-set-aside, competitively awarded contract utilizes firm fixed pricing and represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999 through December 2026. The place...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp for Envarsus XR 4 mg tablets (100-count packaging) on August 27, 2025, with a contract ceiling value of $1,711.95. This firm fixed-price delivery order represents a non-set-aside competitive award and is scheduled for ultimate completion on September 18, 2025. The order will be fulfilled from the vendor's facility in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen Drug...
- The Defense Logistics Agency awarded a delivery order valued at $1,711.95 to AmerisourceBergen Drug Corp for 100 tablets of Envarsus XR 4 mg on August 4, 2025, with an ultimate completion date of August 25, 2025. This firm fixed price, non-set-aside contract represents a pharmaceutical supply delivery executed under a competitively awarded vehicle. The place of performance is listed as Conshohocken, Pennsylvania, where AmerisourceBergen maintains its corporate headquarters and primary...
- The Defense Logistics Agency (DLA) awarded a $2,700.64 firm fixed price delivery order to AmerisourceBergen Drug Corp for 100 tablets of Envarsus XR 4 mg, a tacrolimus-based immunosuppressant medication used primarily in transplant patients. Awarded on August 29, 2025, with an ultimate completion date of September 22, 2025, this non-competitive delivery order represents a routine pharmaceutical supply fulfillment under the company's existing contract vehicle. AmerisourceBergen, headquartered...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 28, 2025, for the supply of Envarsus XR 1 mg tablets in quantities of 100 units. This competitively awarded, firm fixed-price delivery order carries a ceiling value of $1,718.48 and is scheduled for completion by September 19, 2025. The order will be fulfilled from AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. As a child contract action under a larger vehicle, this...
- The Defense Logistics Agency awarded a delivery order valued at $1,718.48 to AmerisourceBergen Drug Corp for the supply of Envarsus XR 1 mg tablets (100-count units) on August 7, 2025, with completion expected by August 28, 2025. This firm fixed price delivery order represents a non-set-aside competitive award to the pharmaceutical distributor's Corporate Office division, with performance to be executed from the company's Conshohocken, Pennsylvania headquarters. The contract falls under...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 19, 2025, for the supply of Envarsus XR 4 mg tablets (100-count units) with a contract ceiling value of $5,135.85. This is a firm fixed-price delivery order with an ultimate completion date of September 10, 2025, and represents no set-aside contract, indicating it was competitively awarded. The work will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This...
- The Defense Logistics Agency awarded a $10,271.70 delivery order to AmerisourceBergen Drug Corp on September 8, 2025, for the supply of Envarsus XR 4 mg tablets (100-count units). This is a firm fixed-price, competitively awarded contract with no set-aside designation and an ultimate completion date of September 29, 2025. The contract will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger...
- SPE2DB22D1202Indefinite Delivery Contract
- SPE2DB22D1202-SPE2DB25FVJZ2Delivery Order
The Defense Logistics Agency (DLA) awarded a delivery order valued at $3,423.90 to AmerisourceBergen Drug Corp for the supply of Envarsus XR 4 mg tablets (100-count units) under a firm fixed price contract. The award, issued on September 2, 2025, with an ultimate completion date of September 23, 2025, represents a non-set-aside competitive award. Performance of this delivery order will be executed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's existing Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), a $999.999 billion prime vendor agreement running through December 2026 that enables the contractor to supply a comprehensive range of pharmaceutical products and medical supplies to support military healthcare programs globally. AmerisourceBergen Drug Corp, one of the nation's largest pharmaceutical distributors and healthcare solutions providers, continues to serve as a critical vendor for federal medical procurement needs through its established relationship with DLA. Envarsus XR, a tacrolimus-based immunosuppressant medication, is essential for transplant patients requiring immunosuppressive therapy within the military healthcare system. The contractor's demonstrated capability in fulfilling federal medical supply requirements through open competition, combined with its extensive portfolio of pharmaceutical deliveries across multiple therapeutic domains, supports its continued role as a preferred provider for Defense Health Agency and other government healthcare systems.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $3.4k | 9/2/25 |